Respiratory Syncytial Virus After CAR T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort

Key Points

• This research aims to identify risk factors and outcomes related to respiratory syncytial virus (RSV) in patients receiving CAR T-cell therapy.
• Retrospective cohort study of 667 CAR T-cell therapy recipients.
• Assessment of RSV incidence and progression to long-term respiratory tract infection (LRTI).
• Analysis of associations between age and lymphopenia with RSV severity.
• 2-year cumulative incidence of RSV was 7% among the cohort.
• 29% of RSV cases progressed to long-term respiratory tract infection (LRTI).
• 74% of infections occurred after day +100, with a median onset of 8 months.